Results 81 to 90 of about 111,907 (307)

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Efficacy of probiotics on the modulation of gut microbiota in the treatment of diabetic nephropathy

, 2022
Diabetic nephropathy (DN) is a major cause of end-stage renal disease, and therapeutic options for preventing its progression are insufficient. The number of patients with DN has been increasing in Asian countries because of westernization of dietary ...
池田 祐香, 1000050242110, Ikeda Yuka, Matsuda Satoru, つじ あい, Kitagishi Yasuko, まつだ さとる, いけだ ゆか, Nagase Nozomi, 辻 愛, Tsuji Ai, 松田 覚   +11 more
core   +1 more source

Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1474-1478, April 2025.
Abstract Aims ZSF1 obese rats harbouring two mutant leptin receptor alleles (Leprcp and Leprfa) develop metabolic syndrome and heart failure with preserved ejection fraction (HFpEF), making them a widely used animal model in cardiometabolic research.
Petra Büttner, Antje Augstein, Mahmoud Abdellatif, André Lourenço, Adelino Leite‐Moreira, Inês Falcão‐Pires, Sarah Werner, Holger Thiele, Simon Sedej, Antje Schauer, Volker Adams   +10 more
wiley   +1 more source

miR-205-5p ameliorates podocyte injury in diabetic nephropathy by targeting vascular endothelial growth factor A

Science Progress
Objective This work aims to elucidate the effect and the regulatory mechanisms of miR-205-5p on podocyte injury and oxidative stress in diabetic nephropathy. Methods A mouse model of diabetic nephropathy was established.
Yingdan Zhao, Yunhai Tang, Qingqing Wang, Xia Wu, Zifan He, Yayun He, Zhihuan Tang   +6 more
doaj   +1 more source

Análise da variabilidade da frequência cardíaca em pacientes diabéticos com e sem nefropatia [PDF]

, 2014
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Programa de Pós-Graduação em Ciências Médicas, Florianópolis, 2014.INTRODUÇÃO: O número de indivíduos com Diabetes Mellitus (DM) vem aumentando de forma ...
Wayhs, Cláudio
core  

Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule [PDF]

, 2009
AIMS/HYPOTHESIS: Microalbuminuria is common in type 1 diabetes and is associated with an increased risk of renal and cardiovascular disease. We aimed to develop and validate a clinical prediction rule that estimates the absolute risk of microalbuminuria.
K. G. M. Moons, P.-H. Groop, S. S. Soedamah-Muthu, M. Rewers, Y. Vergouwe, J. H. Fuller, C. Forsblom, Orchard, T.J., Rewers, M., Forsblom, C., Snell-Bergeon, J.K., T. J. Orchard, Fuller, J.H., D. M. Maahs, J. K. Snell-Bergeon, J. Zgibor, Vergouwe, Y., Moons, K.G.M., N. Chaturvedi, Groop, P.H., Soedamah-Muthu, S.S., Zgibor, J., Maahs, D.M., Chaturvedi, N.   +23 more
core   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Diabetic nephropathy

Disease-a-Month, 1998
Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) and accounts for 35% of the ESRD population in the United States. It results in considerable morbidity, mortality, and expense. The average cost of managing one diabetic patient with ESRD is approximately $50,000 a year.
openaire   +2 more sources

Diabetic Retinopathy in Primary Healthcare in a Brazilian Municipality: A Cross‐Sectional Study Using Teleophthalmology

Health Care Science, EarlyView.
The prevalence of diabetic retinopathy was estimated to be 28.3% (95% CI 21.1–35.4), with most of the cases corresponding to mild non‐proliferative diabetic retinopathy. ABSTRACT Background Diabetic retinopathy is a complication of diabetes and the leading cause of irreversible blindness in people of working age.
Lorrana Luysse dos Anjos Assis, Fernando Korn Malerbi, Rosiane Chiaroti, Lívia Maria Ferrante Vizzotto Consoli, Vanessa Patrícia Pereira Motozo, Francisco Barbosa‐Junior, Rinaldo Eduardo Machado de Oliveira   +6 more
wiley   +1 more source

Angiopoietins and diabetic nephropathy [PDF]

Diabetologia, 2016
Diabetic nephropathy is the main cause of end-stage renal failure in the Western world. In diabetes, metabolic and haemodynamic perturbations disrupt the integrity of the glomerular filtration barrier, leading to ultrastructural alterations of the glomeruli, including podocyte foot process fusion and detachment, glomerular basement membrane thickening,
openaire   +3 more sources